{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:34:25Z","timestamp":1761057265044},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,5,8]],"date-time":"2002-05-08T00:00:00Z","timestamp":1020816000000},"content-version":"vor","delay-in-days":96,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:p> <jats:italic>\n            <jats:bold>Objectives:<\/jats:bold>\n          <\/jats:italic> A clinically important question for any new treatment for bipolar disorder is whether its efficacy extends to patients who have both responded and failed to respond to other mood stabilizers. In this secondary analysis of a placebo\u2010controlled trial demonstrating olanzapine's efficacy for acute mania, we explore whether its usefulness extends to those patients with a history of poor response to other mood stabilizers.\n\n\u2028\u2028<jats:italic><jats:bold>Methods:<\/jats:bold><\/jats:italic> This 4\u2010week, double\u2010blind, placebo\u2010controlled trial studied olanzapine monotherapy 5\u201320 mg\/day for hospitalized patients in acute manic or mixed bipolar episodes. The primary outcome variable was beginning to endpoint change in the Young\u2010Mania Rating Scale (Y\u2010MRS) total score. We investigated whether prospectively identified history of recent failure to respond to other mood stabilizers predicted response to olanzapine.\n\n\u2028\u2028<jats:italic><jats:bold>Results:<\/jats:bold><\/jats:italic> As previously reported, olanzapine\u2010treated patients experienced significantly greater improvement in Y\u2010MRS total score and higher remission rates relative to placebo\u2010treated patients. The current analysis compared these outcome parameters in patients with known poor prior response to lithium and\/or valproate with all other patients and found no significant group by treatment interactions, i.e., treatment effects were not significantly diminished in non\u2010responders to older mood stabilizing agents.\n\n\u2028\u2028<jats:italic><jats:bold>Conclusions:<\/jats:bold><\/jats:italic> Olanzapine has been shown to be superior to placebo for the treatment of mania. This secondary analysis suggests that olanzapine monotherapy is similarly effective for patients whether or not they previously have failed to respond to another mood stabilizer for mania. A study limitation is that response to lithium or valproate was determined retrospectively.<\/jats:p>","DOI":"10.1034\/j.1399-5618.2002.40103.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:49:35Z","timestamp":1047358175000},"page":"43-49","source":"Crossref","is-referenced-by-count":12,"title":["The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania"],"prefix":"10.1111","volume":"4","author":[{"given":"Robert W","family":"Baker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurico","family":"Tohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Den\u00e1i R","family":"Milton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia L","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie M","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.1994.03510360044034","article-title":"Efficacy of divalproex versus lithium and placebo in the treatment of mania","volume":"271","author":"Bowden CL","year":"1994","journal-title":"JAMA"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810250064008"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania","volume":"156","author":"Tohen M","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.17.4.250"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810340047006"},{"key":"e_1_2_6_7_2","first-page":"365","article-title":"Possible predictors of neuroleptic\u2010resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects","volume":"29","author":"Kinon BJ","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_6_8_2","first-page":"51","volume-title":"The Neuroleptic Nonresponsive Patient: Characterization and Treatment","author":"Johns CA","year":"1990"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.149.2.195"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0103"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"429435","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity, and sensitivity","volume":"133","author":"Young RC","year":"1978","journal-title":"Br J Psychiatry"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00002-0"},{"key":"e_1_2_6_15_2","volume-title":"Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder","author":"Tohen M","year":"2000"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830130041008"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.8.1264"},{"key":"e_1_2_6_18_2","first-page":"1391","article-title":"Efficacy of lithium as acute treatment of manic\u2010depressive illness","author":"Stokes PE","year":"1971","journal-title":"Lancet"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-5618.2002.40103.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-5618.2002.40103.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-5618.2002.40103.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T09:01:25Z","timestamp":1697533285000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-5618.2002.40103.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1034\/j.1399-5618.2002.40103.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-5618.2002.40103.x","archive":["Portico"],"relation":{},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}